| pubmed-article:9562569 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0596290 | lld:lifeskim |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0020507 | lld:lifeskim |
| pubmed-article:9562569 | lifeskim:mentions | umls-concept:C0205227 | lld:lifeskim |
| pubmed-article:9562569 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9562569 | pubmed:dateCreated | 1998-5-28 | lld:pubmed |
| pubmed-article:9562569 | pubmed:abstractText | We have previously demonstrated that interleukin-2 (IL-2) receptors, IL-2 protein, and mRNA for IL-2 are present in human carcinomas in vitro and in vivo. Carcinoma cells synchronized in the G2/M-phase of the cell cycle express significantly more intracytoplasmic IL-2 as well as IL-2R-beta and -gamma than tumor cells in the G0/G1-phase. Here we evaluated immunohistologically the cell cycle-dependent distribution of the proliferation-associated Ki-67 antigen and expression of the cytokine IL-2 in four different carcinoma cell lines. In addition, 34 tissue samples from patients with squamous cell carcinomas of the head and neck were simultaneously analyzed for Ki-67 and IL-2 expression and the data were correlated to the histological grade of the tumors. All tumor cell lines were shown to express IL-2 in the Golgi complex. The strongest IL-2 expression was seen in tumor cells undergoing mitosis, identified by double staining with the antibody to Ki-67. In the tumor tissue, the highest level of co-expression of IL-2 and Ki-67 was observed in poorly differentiated carcinomas, with a labeling index (LI) of 67. 2% for IL-2 and 68.8% for Ki-67. Well-differentiated carcinomas showed a significantly lower expression of both proteins (LI 35.0% for IL-2 and 26.5% for Ki-67). The correlation between the labeling indices was statistically significant (r = 0.747; p<0.001). These results demonstrate that IL-2 expression in human carcinoma tissues is strongly associated with cell proliferation and significantly correlates with the histological tumor grade. | lld:pubmed |
| pubmed-article:9562569 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9562569 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9562569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9562569 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9562569 | pubmed:month | May | lld:pubmed |
| pubmed-article:9562569 | pubmed:issn | 0022-1554 | lld:pubmed |
| pubmed-article:9562569 | pubmed:author | pubmed-author:WhitesideT... | lld:pubmed |
| pubmed-article:9562569 | pubmed:author | pubmed-author:JohnsonJ TJT | lld:pubmed |
| pubmed-article:9562569 | pubmed:author | pubmed-author:WatkinsSS | lld:pubmed |
| pubmed-article:9562569 | pubmed:author | pubmed-author:StansonJJ | lld:pubmed |
| pubmed-article:9562569 | pubmed:author | pubmed-author:ReichertT ETE | lld:pubmed |
| pubmed-article:9562569 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9562569 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:9562569 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9562569 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9562569 | pubmed:pagination | 603-11 | lld:pubmed |
| pubmed-article:9562569 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:meshHeading | pubmed-meshheading:9562569-... | lld:pubmed |
| pubmed-article:9562569 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9562569 | pubmed:articleTitle | Endogenous IL-2 in cancer cells: a marker of cellular proliferation. | lld:pubmed |
| pubmed-article:9562569 | pubmed:affiliation | Department of Pathology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA. | lld:pubmed |
| pubmed-article:9562569 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9562569 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9562569 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9562569 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9562569 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9562569 | lld:pubmed |
